John Celebi - 15 Feb 2024 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
SNSE
Transactions as of
15 Feb 2024
Net transactions value
-$4,654
Form type
4
Filing time
16 Feb 2024, 18:28:57 UTC
Previous filing
13 Sep 2023
Next filing
23 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Tax liability $4,654 -5,891 -5.3% $0.7900 105,420 15 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +315,000 $0.000000 315,000 15 Feb 2024 Common Stock 315,000 $0.7900 Direct F2
transaction SNSE Stock Option (Right to Buy) Award $0 +165,889 $0.000000 165,889 15 Feb 2024 Common Stock 165,889 $0.7900 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
F2 The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F3 Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.